Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: batterham rl. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
Inhibition of food intake in obese subjects by peptide YY3-36.
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Batterham RL, et al. N Engl J Med. 2003 Sep 4;349(10):941-8. doi: 10.1056/NEJMoa030204. N Engl J Med. 2003. PMID: 12954742 Free article. Clinical Trial.
Oxyntomodulin suppresses appetite and reduces food intake in humans.
Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR. Cohen MA, et al. Among authors: batterham rl. J Clin Endocrinol Metab. 2003 Oct;88(10):4696-701. doi: 10.1210/jc.2003-030421. J Clin Endocrinol Metab. 2003. PMID: 14557443 Clinical Trial.
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.
Miras AD, Pérez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, Chahal H, Batterham RL, McGowan B, Khan O, Greener V, Ahmed AR, Petrie A, Scholtz S, Bloom SR, Tan TM. Miras AD, et al. Among authors: batterham rl. Lancet Diabetes Endocrinol. 2019 Jul;7(7):549-559. doi: 10.1016/S2213-8587(19)30157-3. Epub 2019 Jun 4. Lancet Diabetes Endocrinol. 2019. PMID: 31174993 Clinical Trial.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Lau DCW, et al. Among authors: batterham rl. Lancet. 2021 Dec 11;398(10317):2160-2172. doi: 10.1016/S0140-6736(21)01751-7. Epub 2021 Nov 16. Lancet. 2021. PMID: 34798060 Clinical Trial.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: batterham rl. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. Diabetes Obes Metab. 2022. PMID: 35441470 Free PMC article. Clinical Trial.
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Garvey WT, et al. Among authors: batterham rl. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. Nat Med. 2022. PMID: 36216945 Free PMC article. Clinical Trial.
159 results